Are Carvedilol and Metoprolol Succinate Comparable Treatments in Heart Failure Patients With Reduced Ejection Fraction
NCT ID: NCT04996550
Last Updated: 2021-08-16
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
NOT_YET_RECRUITING
Total Enrollment
5600 participants
Study Classification
OBSERVATIONAL
Study Start Date
2022-01-03
Study Completion Date
2028-12-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The objective of CROWD-COMPARE is to compare the efficacy of carvedilol and metoprolol succinate on all-cause mortality or first hospitalization for worsening heart failure in patients with heart failure with reduced ejection fraction with an indication for treatment with beta-blockers.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Beta Blocker Treatment on Endothelial Function in Patients With Type 2 Diabetes or Chronic Heart Failure
NCT00497003
Endothelial Function
Beta Blocker
COMPLETED
PHASE4
Comparative Effectiveness of Carvedilol Versus Metoprolol Succinate in Heart Failure Patients With an Implantable Cardioverter Defibrillator
NCT06964464
Heart Failure With Reduced Ejection Fraction (HFrEF)
Sudden Cardiac Death
Ventricular Arrhythmia
+3 more
RECRUITING
PHASE4
Comparative Effects of Nebivolol and Carvedilol on Diastolic Function in the Elderly Heart Failure Patients
NCT02619526
Heart Failure
UNKNOWN
NA
A Phase Ⅲ Study of Extended-Release Carvedilol Sulfate for the Treatment of Heart Failure
NCT02012075
Heart Failure
UNKNOWN
PHASE3
Carvedilol in HF With Preserved EF
NCT05553314
Heart Failure With Preserved Ejection Fraction
Beta Blocker
Myocardial Strain
RECRUITING
PHASE4
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Background:
Heart failure with reduced ejection fraction:
The overall prevalence of heart failure with reduced ejection fraction (HFrEF) is 1-2% in the adult population and increasing with age to more than 10% in the population over 70 years. Patients with HFrEF have markedly reduced life expectancy, physical capacity and quality of life. Activation of the sympathetic nervous system is one of the cardinal pathophysiologic abnormalities in patients with HFrEF. Levels of circulating catecholamines increase in patients with HFrEF in proportion to the severity of the disease and those with the highest plasma levels of norepinephrine have the most unfavorable prognosis.
Beta-blocker in heart failure with reduced ejection fraction:
Prospective randomized clinical trials of sympathetic antagonists with several different beta-blockers have shown that these medications can reduce symptoms, improve left ventricular function, increase functional capacity, decrease the number of hospitalization for worsening heart failure and mortality in patients with HFrEF. Current heart failure guidelines therefore recommend treatment with a beta-blocker in HFrEF patients as a class 1A indication. However, small differences exist between beta-blockers. Metoprolol is a second generation beta-blocker that selectively inhibit β1-adrenoceptors, whereas carvedilol is a third generation beta-blocker, that nonselectively inhibit β1-adrenoceptors with additional inhibition of α1-adrenoceptors. Therefore, controversy exists whether beta-blockers exert a class effect or whether one beta-blocker is superior to another. In the largest prospective randomized clinical trial that directly compared the efficacy of beta-blockers, the Carvedilol or Metoprolol European Trial (COMET), carvedilol increased survival in patients with HFrEF compared with metoprolol tartrate. However, the results of the COMET trial was debated for two reasons. First, it compared carvedilol with the short-acting metoprolol tartrate formulation. Metoprolol tartrate, however, is not the formulation used in key HFrEF metoprolol trials and is not recommended in current heart failure guidelines. Second, the metoprolol tartrate target dose in the COMET trial was 50 mg twice daily, whereas the long-acting metoprolol succinate dose in the Metoprolol CR/XL Randomized Intervention Trial (MERIT) trial was 200 mg once daily,10 as recommended by the heart failure guidelines. Further, Carvedilol was dosed at full guideline target dose in COMET.
No pharmaceutical company has shown interest in carrying out such a comparative study. Attempts have been made to compare these medications based on information from different studies, but these so-called network meta-analyses are severely hampered by having different inclusion and exclusion criteria, different end-points, ect. At the same time the patent of both carvedilol and metoprolol succinate has expired in Denmark.
Objectives:
The objective of CROWD-COMPARE is to compare the efficacy of carvedilol and metoprolol succinate on all-cause mortality or first hospitalization for worsening heart failure in patients with heart failure with reduced ejection fraction with an indication for treatment with beta-blockers.
Methods:
Design and cluster allocation:
CROWD-COMPARE is a crossover comparative effectiveness study with random allocation of clusters. Each participating department of cardiology will be allocated to four periods (clusters): two periods with carvedilol as the principal beta-blocker and two periods with metoprolol succinate as principal beta-blocker. Departments will be randomly allocated as to whether they will begin with the carvedilol or the metoprolol succinate cluster and then alternate between clusters annually.
If a cluster becomes scheduled to stop before four years due to organizational changes (eg. if the department of cardiology associated heart failure clinic is closed or merged with another clinic), the investigators may change the duration of the remaining periods for that cluster in order to get compatible allocation periods for the two medications.
Eligible departments:
All 23 danish departments of cardiology with a heart failure clinic associated, which report to the Danish Heart Failure Registry are eligible.
Treatment in allocation arms:
Treatment in clusters will adhere to Danish and European guidelines, where the indication for beta-blocker treatment is symptomatic heart failure (NYHA ≥ II) with LVEF ≤40%. There is no difference in indication or contraindications for the two medications. Carvedilol or metoprolol succinate will be titrated to target dose (Carvedilol 25 mg twice daily or metoprolol succinate 200 mg once daily) or the maximal tolerated dose according to standard heart failure care. There will not be any extra patient visits due to the study.
Data collection during the allocation period:
As the respective departments of cardiology with an associated heart failure clinic are cluster randomized, there will be no study-related collection of data on individual patients during the allocation period. All data will be obtained from national registries.
Follow-up:
For the purpose of follow-up, data from the Danish Heart Failure Registry, which is routinely uploaded to Statistics Denmark, will be linked in anonymous form to hospital admissions, diagnosis, vital status, cause of death, dispensed descriptions and biochemistry from The Danish National Patient Registry, The Danish Civil Registration System, The Clinical Laboratory Information System and the Danish National Prescription Registry.
The National Prescription Registry entries in Statistics Denmark have a delay of 12 to 18 months, while vital status and admissions are updated with only a few months delay. Hence, the primary endpoint will be assessed two years after the end of the 4-year allocation period. At that time, we will be able to identify patients, who have filled in a prescription for carvedilol or metoprolol succinate during the allocation period. Further, we will have data on survival and hospital admission for a minimum follow-up period of two years.
Data management plan:
All data will be stored and analyzed on the Statistics Denmark servers through our agreement with the Division of Research Services at Statistics Denmark. There is no extra storage of data in relation to this scientific study.
Analysis:
Primary endpoint:
The primary endpoint will be a combined endpoint of all-cause mortality or first hospitalization for worsening heart failure. To have adequate statistical power, we will need an overall event rate of 15% (840 events) for the primary outcome.
Primary analysis:
Proportional hazard regression of time to the primary endpoint from time of first claiming a prescription for carvedilol or metoprolol succinate, comparing carvedilol clusters with metoprolol succinate clusters adjusted for department of cardiology.
Secondary endpoints
* All-cause mortality
* A combined endpoint of all-cause mortality or first hospitalization for worsening heart failure according to heart rhythm (sinus rhythm or atrial fibrillation/flutter)
Secondary analyses:
* Cost-effectiveness analysis of each strategy
* Proportion of patients who remained on beta-blocker treatment for a minimum of one year
* Proportion of patients who switched from their initially prescribed beta-blocker to the other
* Proportion of patients who reached target dose
Intention to treat cohort:
Analyses will be performed on all participating departments of cardiology with an associated heart failure clinic, which report data to the Danish Heart Failure Registry during the study period.
Sample size considerations:
Based on data from the Danish Heart Failure Registry, we expect that 2700 patients annually will be candidates for the treatment with either carvedilol or metoprolol succinate. Some of these patients will already be on betablockers before first visit or hospitalization. In the Danish Heart Failure Registry, 1-year mortality is 10%. With 23 clusters and an estimated overall rate of the primary endpoint of 15% (see above for description of primary endpoint), we will need to recruit registry data from 1400 patients per year (5600 patients in total) to obtain 840 events over a period of four years to detect at relative reduction of 20% between treatment groups with a significance level of 5% and a power of 90% (α=0.05, β=0.10).
Statistics:
Analyses will be performed according to the CONSORT statement recommendation for cluster trials. Statistical analyses will be performed using commercially or open-source available statistical software. Primary results will be assessed as intention-to-treat. In addition, we will conduct an instrumental variable analysis, where the cluster randomization is used as an instrument for actually received treatment. In case of low-compliance to the cluster allocated treatment then instrumental variables is the only way to estimate the causal effect. Continuous data will be presented as median (25-75% range). A two-tailed p value of 0.05 or less is considered statistically significant.
Results for subgroups will be presented. These will be prespecified prior to trial termination.
Ethical aspects:
The two beta-blockers are considered equal in Danish and European heart failure guidelines. Participating departments of cardiology will continue to follow best practice, with each department having one of the two beta-blockers as principal option at a given period of time. Departments who do not wish to switch between principal beta-blockers will not be included. Of importance, all patients will be prescribed the medication that is considered best for them. Hence, all patients will receive the same individually tailored treatment as patients do today at their respective department of cardiology.
Patients will be informed about the trial in two ways: 1) by a posted bulletin in the department stating that the department is participating in CROWD-COMPARE, and 2) by the treating physician informing them, upon prescribing the beta-blocker, that the department is participating in a national effort to compare two equivalent medications, which according to heart failure guidelines are both first-line choices, and that currently the department of cardiology is using the prescribed medication in cases where the patient and treating physician after individual assessment do not have a preference for either beta-blocker.
The price difference between the two beta-blockers varies, but is less than 0.50,- kr./day. (Daily cost: carvedilol 25 mg x 2: 0.63,- kr./day. versus metoprolol succinate 200 mg x 1: 0.57,- kr./day. (April the 30th, 2021). For this reason, the current study will not cause the individual patient nor society (as the patient receives state sponsored premiums for their medications) substantial extra expenses. In case of side effects after the initiation of a beta-blocker, patients can be changed to the other at the discretion of the clinician. The study does not result in extra visits for the patients.
The study follows the Helsinki Declaration II.
Heart failure with reduced ejection fraction:
The overall prevalence of heart failure with reduced ejection fraction (HFrEF) is 1-2% in the adult population and increasing with age to more than 10% in the population over 70 years. Patients with HFrEF have markedly reduced life expectancy, physical capacity and quality of life. Activation of the sympathetic nervous system is one of the cardinal pathophysiologic abnormalities in patients with HFrEF. Levels of circulating catecholamines increase in patients with HFrEF in proportion to the severity of the disease and those with the highest plasma levels of norepinephrine have the most unfavorable prognosis.
Beta-blocker in heart failure with reduced ejection fraction:
Prospective randomized clinical trials of sympathetic antagonists with several different beta-blockers have shown that these medications can reduce symptoms, improve left ventricular function, increase functional capacity, decrease the number of hospitalization for worsening heart failure and mortality in patients with HFrEF. Current heart failure guidelines therefore recommend treatment with a beta-blocker in HFrEF patients as a class 1A indication. However, small differences exist between beta-blockers. Metoprolol is a second generation beta-blocker that selectively inhibit β1-adrenoceptors, whereas carvedilol is a third generation beta-blocker, that nonselectively inhibit β1-adrenoceptors with additional inhibition of α1-adrenoceptors. Therefore, controversy exists whether beta-blockers exert a class effect or whether one beta-blocker is superior to another. In the largest prospective randomized clinical trial that directly compared the efficacy of beta-blockers, the Carvedilol or Metoprolol European Trial (COMET), carvedilol increased survival in patients with HFrEF compared with metoprolol tartrate. However, the results of the COMET trial was debated for two reasons. First, it compared carvedilol with the short-acting metoprolol tartrate formulation. Metoprolol tartrate, however, is not the formulation used in key HFrEF metoprolol trials and is not recommended in current heart failure guidelines. Second, the metoprolol tartrate target dose in the COMET trial was 50 mg twice daily, whereas the long-acting metoprolol succinate dose in the Metoprolol CR/XL Randomized Intervention Trial (MERIT) trial was 200 mg once daily,10 as recommended by the heart failure guidelines. Further, Carvedilol was dosed at full guideline target dose in COMET.
No pharmaceutical company has shown interest in carrying out such a comparative study. Attempts have been made to compare these medications based on information from different studies, but these so-called network meta-analyses are severely hampered by having different inclusion and exclusion criteria, different end-points, ect. At the same time the patent of both carvedilol and metoprolol succinate has expired in Denmark.
Objectives:
The objective of CROWD-COMPARE is to compare the efficacy of carvedilol and metoprolol succinate on all-cause mortality or first hospitalization for worsening heart failure in patients with heart failure with reduced ejection fraction with an indication for treatment with beta-blockers.
Methods:
Design and cluster allocation:
CROWD-COMPARE is a crossover comparative effectiveness study with random allocation of clusters. Each participating department of cardiology will be allocated to four periods (clusters): two periods with carvedilol as the principal beta-blocker and two periods with metoprolol succinate as principal beta-blocker. Departments will be randomly allocated as to whether they will begin with the carvedilol or the metoprolol succinate cluster and then alternate between clusters annually.
If a cluster becomes scheduled to stop before four years due to organizational changes (eg. if the department of cardiology associated heart failure clinic is closed or merged with another clinic), the investigators may change the duration of the remaining periods for that cluster in order to get compatible allocation periods for the two medications.
Eligible departments:
All 23 danish departments of cardiology with a heart failure clinic associated, which report to the Danish Heart Failure Registry are eligible.
Treatment in allocation arms:
Treatment in clusters will adhere to Danish and European guidelines, where the indication for beta-blocker treatment is symptomatic heart failure (NYHA ≥ II) with LVEF ≤40%. There is no difference in indication or contraindications for the two medications. Carvedilol or metoprolol succinate will be titrated to target dose (Carvedilol 25 mg twice daily or metoprolol succinate 200 mg once daily) or the maximal tolerated dose according to standard heart failure care. There will not be any extra patient visits due to the study.
Data collection during the allocation period:
As the respective departments of cardiology with an associated heart failure clinic are cluster randomized, there will be no study-related collection of data on individual patients during the allocation period. All data will be obtained from national registries.
Follow-up:
For the purpose of follow-up, data from the Danish Heart Failure Registry, which is routinely uploaded to Statistics Denmark, will be linked in anonymous form to hospital admissions, diagnosis, vital status, cause of death, dispensed descriptions and biochemistry from The Danish National Patient Registry, The Danish Civil Registration System, The Clinical Laboratory Information System and the Danish National Prescription Registry.
The National Prescription Registry entries in Statistics Denmark have a delay of 12 to 18 months, while vital status and admissions are updated with only a few months delay. Hence, the primary endpoint will be assessed two years after the end of the 4-year allocation period. At that time, we will be able to identify patients, who have filled in a prescription for carvedilol or metoprolol succinate during the allocation period. Further, we will have data on survival and hospital admission for a minimum follow-up period of two years.
Data management plan:
All data will be stored and analyzed on the Statistics Denmark servers through our agreement with the Division of Research Services at Statistics Denmark. There is no extra storage of data in relation to this scientific study.
Analysis:
Primary endpoint:
The primary endpoint will be a combined endpoint of all-cause mortality or first hospitalization for worsening heart failure. To have adequate statistical power, we will need an overall event rate of 15% (840 events) for the primary outcome.
Primary analysis:
Proportional hazard regression of time to the primary endpoint from time of first claiming a prescription for carvedilol or metoprolol succinate, comparing carvedilol clusters with metoprolol succinate clusters adjusted for department of cardiology.
Secondary endpoints
* All-cause mortality
* A combined endpoint of all-cause mortality or first hospitalization for worsening heart failure according to heart rhythm (sinus rhythm or atrial fibrillation/flutter)
Secondary analyses:
* Cost-effectiveness analysis of each strategy
* Proportion of patients who remained on beta-blocker treatment for a minimum of one year
* Proportion of patients who switched from their initially prescribed beta-blocker to the other
* Proportion of patients who reached target dose
Intention to treat cohort:
Analyses will be performed on all participating departments of cardiology with an associated heart failure clinic, which report data to the Danish Heart Failure Registry during the study period.
Sample size considerations:
Based on data from the Danish Heart Failure Registry, we expect that 2700 patients annually will be candidates for the treatment with either carvedilol or metoprolol succinate. Some of these patients will already be on betablockers before first visit or hospitalization. In the Danish Heart Failure Registry, 1-year mortality is 10%. With 23 clusters and an estimated overall rate of the primary endpoint of 15% (see above for description of primary endpoint), we will need to recruit registry data from 1400 patients per year (5600 patients in total) to obtain 840 events over a period of four years to detect at relative reduction of 20% between treatment groups with a significance level of 5% and a power of 90% (α=0.05, β=0.10).
Statistics:
Analyses will be performed according to the CONSORT statement recommendation for cluster trials. Statistical analyses will be performed using commercially or open-source available statistical software. Primary results will be assessed as intention-to-treat. In addition, we will conduct an instrumental variable analysis, where the cluster randomization is used as an instrument for actually received treatment. In case of low-compliance to the cluster allocated treatment then instrumental variables is the only way to estimate the causal effect. Continuous data will be presented as median (25-75% range). A two-tailed p value of 0.05 or less is considered statistically significant.
Results for subgroups will be presented. These will be prespecified prior to trial termination.
Ethical aspects:
The two beta-blockers are considered equal in Danish and European heart failure guidelines. Participating departments of cardiology will continue to follow best practice, with each department having one of the two beta-blockers as principal option at a given period of time. Departments who do not wish to switch between principal beta-blockers will not be included. Of importance, all patients will be prescribed the medication that is considered best for them. Hence, all patients will receive the same individually tailored treatment as patients do today at their respective department of cardiology.
Patients will be informed about the trial in two ways: 1) by a posted bulletin in the department stating that the department is participating in CROWD-COMPARE, and 2) by the treating physician informing them, upon prescribing the beta-blocker, that the department is participating in a national effort to compare two equivalent medications, which according to heart failure guidelines are both first-line choices, and that currently the department of cardiology is using the prescribed medication in cases where the patient and treating physician after individual assessment do not have a preference for either beta-blocker.
The price difference between the two beta-blockers varies, but is less than 0.50,- kr./day. (Daily cost: carvedilol 25 mg x 2: 0.63,- kr./day. versus metoprolol succinate 200 mg x 1: 0.57,- kr./day. (April the 30th, 2021). For this reason, the current study will not cause the individual patient nor society (as the patient receives state sponsored premiums for their medications) substantial extra expenses. In case of side effects after the initiation of a beta-blocker, patients can be changed to the other at the discretion of the clinician. The study does not result in extra visits for the patients.
The study follows the Helsinki Declaration II.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Chronic Heart Failure
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
COHORT
Study Time Perspective
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Carvedilol group
Treated with Carvedilol
Carvedilol
Intervention Type
DRUG
To compare the efficacy of carvedilol and metoprolol succinate on all-cause mortality or first hospitalization for worsening heart failure in patients with heart failure with reduced ejection fraction with an indication for treatment with beta-blockers.
Metoprolol succinate group
Treated with Metoprolol succinate
Metoprolol Succinate
Intervention Type
DRUG
To compare the efficacy of carvedilol and metoprolol succinate on all-cause mortality or first hospitalization for worsening heart failure in patients with heart failure with reduced ejection fraction with an indication for treatment with beta-blockers.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Carvedilol
To compare the efficacy of carvedilol and metoprolol succinate on all-cause mortality or first hospitalization for worsening heart failure in patients with heart failure with reduced ejection fraction with an indication for treatment with beta-blockers.
Intervention Type
DRUG
Metoprolol Succinate
To compare the efficacy of carvedilol and metoprolol succinate on all-cause mortality or first hospitalization for worsening heart failure in patients with heart failure with reduced ejection fraction with an indication for treatment with beta-blockers.
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age ≥18 years
* NYHA ≥ II
* LVEF ≤40%
* NYHA ≥ II
* LVEF ≤40%
Exclusion Criteria
* No indication for beta-blocker treatment or contraindications for the two for the two study drugs (Carvedilol or metoprolol succinate)
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Odense University Hospital
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mikael Kjaer Poulsen
Principal Investigator
Responsibility Role
PRINCIPAL_INVESTIGATOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Cardiology, Odense University Hospital
Odense, Region Syddanmark, Denmark
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Denmark
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CROWD-COMPARE
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Danish Carvedilol Study in Portal Hypertension
NCT00493480
COMPLETED
PHASE3
The Development of Tolerance to α1-Adrenoceptor Blockade With Chronic Carvedilol Treatment
NCT00585091
COMPLETED
NA
Pharmacodynamic Study of Carvedilol Versus Metoprolol in Heart Failure
NCT00802230
COMPLETED
PHASE4
Indacaterol in Heart Failure Patients: Any Role on Lung Fluid Regulation
NCT02598505
COMPLETED
PHASE3
Tolerability of Metoprolol-Succinate-ER and Carvedilol in COPD
NCT03370835
COMPLETED
PHASE4
The Effect of Metoprolol in Patients With Hypertrophic Obstructive Cardiomyopathy.
NCT03532802
COMPLETED
PHASE2
Nebivolol Versus Carvedilol in Patients With Heart Failure
NCT00511888
TERMINATED
Metoprolol and Formoterol in Chronic Obstructive Pulmonary Disease (COPD)
NCT00288548
UNKNOWN
PHASE4
pErsonalised Nocebo Assessment of Beta-blockEr Symptoms in Heart Failure
NCT07029906
RECRUITING
NA
A Phase Ⅲ Study of Extended-Release Carvedilol Sulfate for the Treatment of Hypertension
NCT01970059
UNKNOWN
PHASE3
Ability of Metoprolol to Alter the Exercise Induced Elevation of Catecholamines
NCT00885651
UNKNOWN
PHASE4
Nebivolol Versus Bisoprolol Versus Carvedilol in Heart Failure
NCT00517725
COMPLETED
PHASE4
Effect of Beta Blockade on Left Ventricular Remodeling and Function in Moderate to Severe Asymptomatic Aortic Regurgitation
NCT01157572
COMPLETED
PHASE4
A Crossover Study to Evaluate the Effect of JNJ-54452840 on Pharmacodynamics of Metoprolol Tartrate Immediate-Release in Healthy Participants
NCT01902550
WITHDRAWN
PHASE1
Assay to Measure Beta Blocker Adherence
NCT05251974
TERMINATED
Nebivolol Versus Metoprolol: Sodium Sensitivity
NCT00992056
COMPLETED
PHASE4
Comparing the Effects of Two Beta Blockers,Metoprolol and Nebivolol,on Ambulatory Blood Pressure and Basal Metabolic Rate
NCT00849810
TERMINATED
NA
Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension
NCT05593055
RECRUITING
PHASE4
Effect of Metoprolol in Post Alcohol Septal Ablation Patients With Hypertrophic Cardiomyopathy
NCT04133532
COMPLETED
PHASE4
The Influence of Beta Blocker Therapy on the Hemodynamic Response to Inotrope Infusion in Patients With Acute Decompensated Heart Failure
NCT01971944
COMPLETED
Effect of METOprolol in CARDioproteCtioN During an Acute Myocardial InfarCtion. The METOCARD-CNIC Trial.
NCT01311700
COMPLETED
PHASE4
Vascular Effects of Carvedilol Versus Metoprolol in Hypertensive Patients With Type 2 Diabetes
NCT00123604
COMPLETED
PHASE4
Comparison of Two Medications Aimed at Slowing Aortic Root Enlargement in Individuals With Marfan Syndrome
NCT00429364
COMPLETED
PHASE3
Collaborative Systematic Overview of Randomised Controlled Trials of Beta-Blockers in the Treatment of Heart Failure
NCT00832442
UNKNOWN
Effect of Beta-blockers on Structural Remodeling and Gene Expression in the Failing Human Heart
NCT01798992
COMPLETED
PHASE4